Login / Signup

Risk of immunotherapy-related narcolepsy in genetically predisposed patients: a case report of narcolepsy after administration of pembrolizumab.

Yutaka NatoriEisaku SasakiShu SoedaShigenori FurukawaYusuke AzamiEmi TokudaTakashi KanbayashiShigehira Saji
Published in: Journal for immunotherapy of cancer (2021)
This case suggests that treatment with immune checkpoint inhibitors potentially causes narcolepsy in genetically predisposed patients.
Keyphrases
  • end stage renal disease
  • ejection fraction
  • newly diagnosed
  • chronic kidney disease
  • prognostic factors
  • patient reported outcomes
  • tyrosine kinase